Genomic Unraveling of Biological & Clinical Heterogeneity in Medulloblastoma

Paul A. Northcott, PhD
Principal Investigator | Associate Member
Department of Developmental Neurobiology
St. Jude Children’s Research Hospital
Memphis, TN, USA

This conference is hosted by Frédéric Charron, PhD. This conference is part of the 2023-2024 IRCM conference calendar.

In person: 
IRCM Auditorium
110, avenue des Pins O, H2W 1R7 Montreal

Online:
Zoom Link : https://zoom.us/j/95269762104
ID : 952 6976 2104
Code : 476372

IRCM conferences are set to occur under a hybrid format. However, please note that last-minute changes to online-only lectures may occur due to unforeseen circumstances. We invite you to visit this webpage again a few days before attending.

About this conference
TBD

About Paul A. Northcott

Dr. Paul A. Northcott is a Member in the Department of Developmental Neurobiology and Neurobiology and Brain Tumor Program at St. Jude Children’s Research Hospital. During his PhD and postdoctoral training, Dr. Northcott made numerous impactful contributions to the medulloblastoma literature, including the original description of molecularly and clinically distinct WHO subgroups, consortia-level annotation of genomic and epigenomic landscapes, and the discovery of ‘enhancer hijacking’ as a novel mechanism of oncogene activation in brain tumors. 

Dr. Northcott is an active Member of the Children’s Oncology Group, the American Association of Cancer Research, and the Society for Neuro-Oncology. He has led several high-impact studies published in Nature, Nature Genetics, Cancer Cell, Lancet Oncology and Journal of Clinical Oncology, disclosing the molecular mechanisms underlying medulloblastoma pathogenesis, and establishing the importance of contextualizing clinical trial outcomes with biology. He is the recipient of numerous prestigious awards at both the trainee and principal investigator level, including The Sontag Foundation Distinguished Scientist Award, Pew-Stewart Scholar for Cancer Research, St. Baldrick’s Foundation Robert J. Arceci Innovation Award, and was an inaugural recipient of the AACR NextGen Grant for Transformative Cancer Research.

The Northcott Lab uses a variety of multidimensional genomic and functional approaches to study the molecular basis of medulloblastoma initiation, maintenance, progression, and relapse. The overarching goal of these efforts is to enhance diagnosis, treatment, and outcomes for affected children and their families.
 

To make sure you don't miss any of the IRCM conferences, sign up now for our newsletter!